 |
|
|
|
|
|
|
| NexCura Websites: |
| NEWS: US Oncology announces expanded educational resources to cancer patients through new affiliations with CURE & NexCura |
READ MORE > |
|
|
Medical Editorial Board
|
|
Jonathan S. Berek, M.D., M.M.Sc. - Ovarian Cancer, Uterine Cancer, Cervical Cancer
Professor and Chair, Department of Obstetrics and Gynecology, Stanford University School of Medicine
Chief of Obstetrics and Gynecology, Stanford University Hospital and Clinics
Dr. Berek is Professor and Chair of the Department of Obstetrics and Gynecology at Stanford University School of Medicine, the Chief of Obstetrics and Gynecology at Stanford Hospital & Clinics, as well as Co-Director of the Women's Cancer Program at the Stanford Cancer Center.
Dr. Berek is known for his expertise in gynecologic oncology and pelvic reconstructive surgery, and for his research in ovarian cancer as well as the immunology and immunotherapy of gynecologic malignancies. His primary areas of interest are in the development of novel therapies and vaccines for ovarian cancer. He has contributed over 400 publications to the scientific literature. He is the Group Chair and Principal Investigator of the Cooperative Group for Immunotherapy in Ovarian Cancer (COGI), funded by the Ovarian Cancer Research Fund (OCRF).
Before joining Stanford in December of 2005, Dr. Berek spent more than two decades at UCLA where he was Chair of the College of Applied Anatomy at the David Geffen School of Medicine at UCLA, the Executive Vice Chair of the Department of Obstetrics and Gynecology, Chief of the Division of Gynecologic Oncology and the Gynecology Service, Director of the UCLA Women's Reproductive Cancer Program, and Chief of Staff of the UCLA Medical Center.
Dr. Berek received an undergraduate degree in 1970 from Brown University in English and American Literature/Theatre Arts and Dramatic Literature, and an MMS in Biomedical Sciences in 1973 from Brown. After receiving his medical degree from Johns Hopkins University School of Medicine in 1975, he completed an internship, residency, and fellowship at Harvard Medical School, the Brigham & Women's Hospital. He completed his fellowship in Gynecologic Oncology at the UCLA School of Medicine in 1981. He was elected to Phi Beta Kappa, Alpha Omega Alpha, and Sigma Xi Honor Societies. He is a fellow in the American College of Obstetricians & Gynecologists and the American College of Surgeons.
Well respected in the fields of gynecology and gynecologic oncology, Dr. Berek has repeatedly appeared on lists of America's Top Doctors and Cancer Specialists and in Who's Who compilations. Dr. Berek is well known as an author, having written 10 books, most notably two of the most popular textbooks in his specialty, Berek & Novak's Gynecology, and Berek & Hacker's Gynecologic Oncology.
Dr. Berek is the President of the International Gynecologic Cancer Society. His many awards include the Sherman Mellinkoff Faculty Award and the Excellence in Education Award, both from UCLA, and he is a six-time recipient of the UCLA Excellence in Teaching Award. He received the President's Award from the Society of Gynecologic Oncologists, and he was named to the prestigious Bethesda II and III committees of the National Institutes of Health. In 2007, he was nominated for Time magazine's Person of the Year for his work in international women’s cancer.
Dr. Richard J. Gralla, M.D. - Small Cell Lung Cancer, Non-Small Cell Lung Cancer
President, New York Lung Cancer Alliance
 Dr. Gralla is currently Vice President for Cancer Services and Chief of the Division of Hematology and Oncology at the Monter Cancer Center of the North Shore-LIJ Health System in Lake Success, New York. Prior to accepting that position, he was Professor of Medicine, at Columbia University, in New York. He has also been the Chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center (New York), and Director of the Ochsner Cancer Institute in New Orleans, Louisiana.
Dr. Gralla received his medical degree from the University of Virginia in Charlottesville. He completed a fellowship in medical oncology and was a National Cancer Institute fellow in clinical research at Memorial Sloan-Kettering Cancer Center.
Dr. Gralla is the author or co-author of over 220 scientific articles and book chapters. His work has been published in journals such as the New England Journal of Medicine, Annals of Internal Medicine, Journal of Clinical Oncology, Cancer, and Cancer Research. Dr. Gralla serves on the editorial boards of Cancer, Lung Cancer, and Supportive Care in Cancer. He is a board member of the oncology section of the International Society for Chemotherapy, a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association for the Study of Lung Cancer. Dr. Gralla is the Past-President of the Multinational Association of Supportive Care in Cancer and Past-President of the New York Lung Cancer Alliance.
Richard T. Hoppe, M.D., F.A.C.R. - All Cancer Tools
Henry S. Kaplan - Harry Lebeson Professor and Chairman Department of Radiation Oncology, Stanford University School of Medicine
 Dr. Hoppe has chaired the Department of Radiation Oncology at Stanford University School of Medicine since 1994. He is also vice chair of the Department of Radiation Oncology at Santa Clara Valley Medical Center and a member of the Board of Stanford University Hospital.
His research interests include: Hodgkin's disease, the non-Hodgkin's lymphomas, mycosis fungoides, radiation immunosuppression (total lymphoid irradiation), total body irradiation, and bone marrow transplantation. He has co-authored more than 200 research articles, and contributed to more than 75 books on radiation oncology. He is a co-editor of the textbook Hodgkin's Disease, published in 1999.
Dr. Hoppe completed his undergraduate and doctor of medicine degrees at Cornell University in New York. He interned at Cornell Cooperating Hospitals-North Shore Hospital and Memorial Hospital in New York, and completed a postdoctoral fellowship in radiation therapy and cancer biology research at Stanford University, Stanford, Calif.
Dr. Hoppe serves on the editorial boards of the International Journal of Radiation Oncology, Biology and Physics, Oncology Times, Advanced Medical Publishing, The Cancer Journal of the Scientific American among others. He is board certified by the American Board of Radiology in Therapeutic Radiology.
His numerous academic and public honors include Fellowship in the American College of Radiology; The E. Richard King Memorial Lecture of the Medical College of Virginia; Best Cancer Specialists in the US, Good Housekeeping; The Best Doctors in America, American Health; and The Best Doctors in America: Pacific Region. He has delivered the Radiation Oncology Oration at the Annual Scientific Meeting of the Radiological Society of North America, the Vera Peters Lecture at the Princess Margaret Hospital, and he received the Janeway Award from the American Radium Society. Dr. Hoppe is a former President and Chairman of the Board of the American Society for Therapeutic Radiology and Oncology, and he is a member of the American College of Radiology and the American Society of Clinical Oncology. He serves as a Trustee of the American Board of Radiology.
Vivek K. Mehta, M.D. - Colorectal Cancer
Radiation Oncology, Swedish Cancer Institute,
 Dr. Mehta is actively involved in designing and developing clinical research studies at the Swedish Cancer Institute in Seattle, WA and through national research organizations, including the Southwestern Oncology Group (SWOG). He has written extensively about the use of concurrent chemotherapy and radiation in the management of malignancy and presented findings at national and international meetings.
His clinical interests include balloon catheter based breast brachytherapy, gamma knife radiosurgery, intensity modulated radiotherapy, stereotactic radiosurgery, targeted radiolabeled antibodies, three-dimensional conformal radiotherapy. He is also interested in assisting patients understand the wide variety of treatment options available for nearly every patient. He believes it is important to spend much time as is needed to help patients weigh the benefits and risks to any particular approach. He believes in flexibility and tailoring treatment to the individual situation, which sometimes means using techniques perfected over the years and at other times incorporating newer more investigational or "cutting-edge" approaches. The key is open and honest communication. The goals of treatment, whether it is going for "cure" or maximizing "quality of life," should be openly discussed and rediscussed as the need arises.
Dr. Mehta earned his doctor of medicine degree at the University of Washington, WA, served his residency at Stanford University in Palo Alto, CA and his internship at Good Samaritan in Portland OR. He is board certified in Therapeutic Radiology.
His many honors include Seattle's Top Doctors List, Seattle Magazine, August 2004; the Malcolm A. Bagshaw Radiation Oncology Resident Award, 2001; the ASCO Resident/Fellow Research Award, 2001; the RSNA-Roentgen Resident/Fellow Research Award, 2000.
Marcus Neubauer, MD - Small Cell Lung Cancer, Non-Small Cell Lung Cancer
Medical Oncologist, Kansas City Cancer Center, Overland Park, KS
 Dr. Neubauer is a physician with Kansas City Cancer Center (KCCC). He is the chair of their pharmacy and therapeutics committee and quality improvement committee. KCCC has been a QOPI participant for 3 years and Dr. Neubauer is the practice’s QOPI physician lead.
Dr. Neubauer is US Oncology’s Level 1 Pathways Task Force chair (since inception) and also spent 6 years as US Oncology’s lung research committee co-chair. He serves on US Oncology’s Pharmacy and Therapeutics executive committee and he is a co-medical director of Innovent Oncology. Dr. Neubauer is also past-president of Kansas Society of Clinical Oncology (KSCO) and past member of ASCO’s clinical practice committee.
He is a member of ASCO and is board certified in internal medicine and medical oncology. Honors include “Top 10 doctors in Kansas City” by Ingram’s Magazine in 2004.
Walter Stadler, M.D., F.A.C.P. - Bladder Cancer, Kidney Cancer, Testicular Cancer, Prostate Cancer
Fred C. Buffett Professor of Medicine & Surgery, Associate Dean of Clinical Research,, Director of Genitourinary Oncology, University of Chicago
 Dr. Stadler received his undergraduate degree from the University of Illinois and his M.D. from Yale University School of Medicine. He received postgraduate training at Michael Reese Hospital and Medical Center as well as the University of Chicago.
He is a medical oncologist whose research focuses on novel therapeutic approaches to genitourinary malignancies. He is the Associate Dean of Clinical Research, an executive board member for the University of Chicago Clinical and Translational Science Award (CTSA), co-director of the Northwestern/University of Chicago Prostate Cancer Specialized Program Of Research Excellence (SPORE), and is the renal cell cancer cadre leader for Genitourinary Cancer Committee within the Cancer and Leukemia Group B.
He has over 100 publications in this area and serves as a reviewer for a broad range of oncology journals. He is an active member of a number of cancer and urology related societies including American Society of Clinical Oncology, American Urology Association, American Association for Cancer Research, and Society of Urologic Oncology.
His work has been supported by a number of agencies and societies including the American Cancer Society, the National Institute of Health, and the Kidney Cancer Association and he serves on various peer review committees. He continues as principal investigator on a number of bladder, kidney, and prostate investigative protocols and is a sought after lecturer on therapeutic aspects of these malignancies
Nicholas J. Vogelzang, M.D., Emeritus Board Member - Prostate Cancer, Bladder Cancer, Kidney Cancer, Testicular Cancer
Director, Nevada Cancer Institute
 Dr. Vogelzang is a world-renowned medical oncologist and internist. Now director of the Nevada Cancer Institute, Vogelzang formerly directed the University of Chicago's Cancer Research Center and department of Genitourinary Oncology.
Dr. Volgelzang is an active member in a number of important medical societies, including the American Urological Association, the Society of Urologic Oncology, and the American Society of Clinical Oncology. He has served on dozens of local and national committees under the auspices of the National Cancer Institute (NCI), the American Society of Clinical Oncology (ASCO), the American Cancer Society (ACS), the American Association for Cancer Research (AACR), and the Cancer and Leukemia Group B (CALGB), to name a few.
Dr. Volgelzang was most recently elected to the board of directors of the Association of American Cancer Institutes. He also is a committee member for the National Cancer Institute Study Section H of the NIH/NCI, and serves on the advisory boards of the Cancer Wellness Center in Skokie, IL, and the Wellness House in Hinsdale, IL.
He is a reviewer for many medical journals, including: New England Journal of Medicine, Journal of the American Medical Association, Cancer, Cancer Investigation, Cancer Research, Journal of Clinical Oncology, Journal of National Cancer Institute, Journal of Urology, Urology, and Prostate.
He is on the Medical Advisory Board of US Too, 2000, and is on the editorial boards of One – Oncology Economics, Cancer Research, Cancer, The Prostate Journal, New Developments in Prostate Cancer Treatment, Seminars in Oncology, Journal of Clinical Oncology, and others.
Dr. Vogelzang has received many honors and awards, most recently receiving the 1999 American Cancer Society St. George National Award and the Fred C. Buffett Chair in Genitourinary Oncology. He has won numerous grants and contracts, from organizations such as Abbott Laboratories, Lilly Research Laboratories, and NIH/NCI, for his groundbreaking cancer research. His work has been published in nearly 200 articles in leading medical journals, and he has lectured widely on the topic of cancer treatment, giving a number of talks on prostate cancer and bladder cancer.
William C. Wood, M.D. - Breast Cancer
Chief of Surgery, Emory University Hospital; Whitehead Professor and Chairman, Department of Surgery, Emory University School of Medicine; Clinical Director, Winship Cancer Institute, Atlanta, Ga.
 As chair of surgery since 1991, Dr. Wood oversees the clinical and research programs of the Department of Surgery. He also heads the Breast Cancer Program of the Winship Cancer Institute at Emory University School of Medicine. His current research interests focus on improving disease-free and overall-survival in breast cancer patients.
Having published more than 250 research studies over the past 30 years, Dr. Wood has been a major influence on national and international trends in cancer therapy. He served as chairman of the 1990 National Institutes of Health Consensus Development Conference on Management of Early Breast Cancer, and for 10 years chaired the Breast Cancer Committee of the Cancer and Leukemia Group B, a NIH cooperative group of 21 major cancer centers committed to cooperative research and clinical trials, and for eight years chaired the Breast Cancer Committee of the Eastern Cooperative Oncology Group.
Before joining Emory University Medical School, he served as both the medical director of the cancer center and chief of surgical oncology at Massachusetts General Hospital, Boston, MA.
Dr. Wood also has served on numerous national oncology committees and is currently president of the Society of Surgical Oncology. He is a member of the board of governors for the American College of Surgeons. Dr. Wood is a member of the medical advisory board for the National Alliance of Breast Cancer Organizations; and chairs the NIH/NCI Clinical Trials Cooperative Groups Breast Intergroup Committee and co-chairs the Early Breast Cancer Trialists’ Collaborative Group, Oxford, United Kingdom.
Dr. Wood earned his medical doctorate from Harvard Medical School in 1966 and completed his internship at Massachusetts General Hospital, where he also served as assistant and chief resident in surgery. He completed fellowship training at the National Institutes of Health and Harvard Medical School.
He is a member of numerous editorial boards and professional societies. Dr. Wood is an editor-in-chief of Oncology and associate editor of the American Journal of Clinical Oncology. He serves as a member of the American Association for Cancer Research, the American Association of Immunologists, American College of Surgeons and American Society of Clinical Oncology (ASCO), among many others.
|
|
